TORONTO, Dec. 19 /CNW/ - Trillium Therapeutics Inc. (Trillium) today announced that its gastrointestinal product, TTI-1612, has been designated an Orphan Drug by the European Medicines Agency (EMEA), and the U.S. Food and
Drug Administration (FDA), for the prevention of necrotizing enterocolitis (NEC).
